Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Sanofi To Buy Pluromed - Quick Facts

Sanofi (SNY: Quote,SNYNF.PK) and Pluromed Inc. announced that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts.

As part of the agreement, Sanofi will commercialize Pluromed's LeGoo, a highly innovative FDA approved and CE marked gel for temporary endovascular occlusion of blood vessels during surgical procedures.

Alison Lawton, senior vice president and general manager, Sanofi Biosurgery, commented, "The acquisition of Pluromed underscores Sanofi's commitment to strengthen its Biosurgery portfolio. LeGoo is a breakthrough technology with the potential to change the paradigm of vascular and cardiovascular surgical procedures, by providing fast, temporary control of blood flow while avoiding vessel trauma associated with standard of care."

Click here to receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After turning in a lackluster performance for much of the session, stocks managed to end Wednesday's trading mostly higher. The gains lifted the Dow and the S&P 500 to new record closing highs, while the Nasdaq reached its best levels since 2000. Half of Americans agree with the changes to immigration policy announced by President Barack Obama last week, according to a CNN/ORC poll, although a majority opposes using executive orders to implement those policies. While Mitt Romney has said he has no plans to run for president again, the results of a Quinnipiac University national poll released Wednesday show the former Massachusetts Governor leading a group of potential Republican presidential candidates.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.